BACKGROUND: It is unknown whether preeclampsia is a risk marker for subsequent end-stage renal disease (ESRD). METHODS: We linked data from the Medical Birth Registry of Norway, which contains data on all births in Norway since 1967, with data from the Norwegian Renal Registry, which contains data on all patients receiving a diagnosis of end-stage renal disease (ESRD) since 1980, to assess the association between preeclampsia in one or more pregnancies and the subsequent development of ESRD. The study population consisted of women who had had a first singleton birth between 1967 and 1991; we included data from up to three pregnancies. RESULTS: ESRD developed in 477 of 570,433 women a mean (+/-SD) of 17+/-9 years after the first pregnancy (overall rate, 3.7 per 100,000 women per year). Among women who had been pregnant one or more times, preeclampsia during the first pregnancy was associated with a relative risk of ESRD of 4.7 (95% confidence interval [CI], 3.6 to 6.1). Among women who had been pregnant two or more times, preeclampsia during the first pregnancy was associated with a relative risk of ESRD of 3.2 (95% CI, 2.2 to 4.9), preeclampsia during the second pregnancy with a relative risk of 6.7 (95% CI, 4.3 to 10.6), and preeclampsia during both pregnancies with a relative risk of 6.4 (95% CI, 3.0 to 13.5). Among women who had been pregnant three or more times, preeclampsia during one pregnancy was associated with a relative risk of ESRD of 6.3 (95% CI, 4.1 to 9.9), and preeclampsia during two or three pregnancies was associated with a relative risk of 15.5 (95% CI, 7.8 to 30.8). Having a low-birth-weight or preterm infant increased the relative risk of ESRD. The results were similar after adjustment for possible confounders and after exclusion of women who had kidney disease, rheumatic disease, essential hypertension, or diabetes mellitus before pregnancy. CONCLUSIONS: Although the absolute risk of ESRD in women who have had preeclampsia is low, preeclampsia is a marker for an increased risk of subsequent ESRD. 2008 Massachusetts Medical Society
BACKGROUND: It is unknown whether preeclampsia is a risk marker for subsequent end-stage renal disease (ESRD). METHODS: We linked data from the Medical Birth Registry of Norway, which contains data on all births in Norway since 1967, with data from the Norwegian Renal Registry, which contains data on all patients receiving a diagnosis of end-stage renal disease (ESRD) since 1980, to assess the association between preeclampsia in one or more pregnancies and the subsequent development of ESRD. The study population consisted of women who had had a first singleton birth between 1967 and 1991; we included data from up to three pregnancies. RESULTS:ESRD developed in 477 of 570,433 women a mean (+/-SD) of 17+/-9 years after the first pregnancy (overall rate, 3.7 per 100,000 women per year). Among women who had been pregnant one or more times, preeclampsia during the first pregnancy was associated with a relative risk of ESRD of 4.7 (95% confidence interval [CI], 3.6 to 6.1). Among women who had been pregnant two or more times, preeclampsia during the first pregnancy was associated with a relative risk of ESRD of 3.2 (95% CI, 2.2 to 4.9), preeclampsia during the second pregnancy with a relative risk of 6.7 (95% CI, 4.3 to 10.6), and preeclampsia during both pregnancies with a relative risk of 6.4 (95% CI, 3.0 to 13.5). Among women who had been pregnant three or more times, preeclampsia during one pregnancy was associated with a relative risk of ESRD of 6.3 (95% CI, 4.1 to 9.9), and preeclampsia during two or three pregnancies was associated with a relative risk of 15.5 (95% CI, 7.8 to 30.8). Having a low-birth-weight or preterm infant increased the relative risk of ESRD. The results were similar after adjustment for possible confounders and after exclusion of women who had kidney disease, rheumatic disease, essential hypertension, or diabetes mellitus before pregnancy. CONCLUSIONS: Although the absolute risk of ESRD in women who have had preeclampsia is low, preeclampsia is a marker for an increased risk of subsequent ESRD. 2008 Massachusetts Medical Society
Authors: Feng Li; John R Hagaman; Hyung-Suk Kim; Nobuyo Maeda; J Charles Jennette; James E Faber; S Ananth Karumanchi; Oliver Smithies; Nobuyuki Takahashi Journal: J Am Soc Nephrol Date: 2012-01-26 Impact factor: 10.121
Authors: Andrea E Cassidy-Bushrow; Lawrence F Bielak; Andrew D Rule; Patrick F Sheedy; Stephen T Turner; Vesna D Garovic; Patricia A Peyser Journal: J Womens Health (Larchmt) Date: 2009-10 Impact factor: 2.681
Authors: Wendy L Bennett; Marta M Gilson; Roxanne Jamshidi; Anne E Burke; Jodi B Segal; Kimberley E Steele; Martin A Makary; Jeanne M Clark Journal: BMJ Date: 2010-04-13
Authors: Richard J Levine; Lars J Vatten; Gary L Horowitz; Cong Qian; Pal R Romundstad; Kai F Yu; Anthony N Hollenberg; Alf I Hellevik; Bjorn O Asvold; S Ananth Karumanchi Journal: BMJ Date: 2009-11-17